Therapeutic drug monitoring of methotrexate by disposable SPCE biosensor for personalized medicine

• Published in: Analytica chimica acta 2025-01, Vol.1335, p.343473, Article 343473
• Main Authors: Liu, Hui, Liu, Yi-Wei, Yang, Ruo-Yu, Wu, Mei-Juan, Yu, Zi-Wei, Han, Jing-Wen, Zhang, Chen-Zhi, Huang, Pin-Fang, Liu, Ai-Lin, Liu, Meng-Meng
• Format: Article
• Language: English
• Subjects: Antimetabolites, Antineoplastic - analysis; Antimetabolites, Antineoplastic - blood; Biosensing Techniques; Carbon - chemistry; Drug Monitoring - methods; Electrochemical sensor; Electrochemical Techniques - instrumentation; Electrochemical Techniques - methods; Electrodes; Humans; Limit of Detection; Methotrexate; Methotrexate - analysis; Methotrexate - blood; Precision Medicine; Therapeutic drug monitoring; Wide linear range
• ISSN: 0003-2670; 1873-4324; 1873-4324
• DOI: 10.1016/j.aca.2024.343473

Methotrexate (MTX) is widely used in clinical practice for the treatment of malignant tumors and autoimmune diseases. High-dose MTX has been shown to be an effective approach for treating various malignant tumors, but it is accompanied by numerous toxic side effects, necessitating therapeutic drug monitoring (TDM) for patients and timely “folinic acid rescue.” High-performance liquid chromatography and fluorescent immunoassay (FIA) are currently used to detect MTX, but these methods are limited by complex sample preparation, time consumption, and high cost. Therefore, a simple, rapid, and cost-effective MTX measurement method is required. We developed a flexible and inexpensive electrochemical sensor using a stearyl trimethyl ammonium bromide (STAB)-modified, screen-printed carbon electrode to directly detect MTX in human serum. Assay performance was validated via detection of MTX in spiked buffer. The sensor was capable of measuring MTX concentrations ranging from 0.01 to 1 μM and 1–1500 μM, with a limit of detection of 3.1 nM and a limit of quantitation of 3.5 nM. For the samples simulating combined medication, the sensor exhibited outstanding selectivity, in cross-reactivity, with the maximum response value of interferents reaching only 3.49 %. Additionally, the sensor shows reliable repeatability with a relative standard deviation of 3.8 % and remarkable stability. Recovery in human serum validated the clinical utility of the sensor in point-of-care testing conditions. The sensor's applicability to personal medicine was confirmed by detecting MTX blood concentration in patients with different diseases. The results obtained by the sensor were compared with those obtained by the FIA technique, a method commonly used in hospitals, showing a high level of consistency between both methods. To meet the requirements of personalized medicine for MTX-patients, we developed a disposable biosensor with wide detection range from 0.01 to 1 μM and 1–1500 μM. Owing to the effective enrichment of STAB, the electrochemical response was sensitive, selective, stable, and rapid. As per the clinical test results, our sensor has shown a high level of consistency with the FIA method, indicating its potential to replace FIA as a cost-effective platform for MTX-TDM. [Display omitted] •SATB, a kind of cationic surfactants, was used to enrich MTX to achieve rapid response.•The developed sensor has wide linearity range from 0.01 to 1500 μM with LOD of 3.1 nM.•The sensor displayed